Minnesota's Solventum sells purification business to Thermo Fisher for $4.1 billion
M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to pay down its billions in outstanding debt. Solventum CEO Bryan Hanson said in a news release that the sale,
Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...
Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...
Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Amy Wakeham; SVP of IR; Solventum Corp. Bryan Hanson; CEO & Director; Solventum Corp. Wayde McMillan; CFO; Solventum Corp. Jason Bednar; Analyst; Piper Sandler & Co.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback